8-K: ModivCare Secures $105 Million in Financing and Appoints Chief Transformation Officer

ModivCare has obtained $105 million in new financing, appointed a Chief Transformation Officer, and is pursuing a strategic review of assets to improve its financial position and operational performance.

Summary

• ModivCare has secured $75 million in an incremental term loan and $30 million in new second lien notes.
• The company has appointed Chad Shandler as Chief Transformation Officer.
• A strategic review of assets is underway to maximize shareholder value.
• Revolving lenders have agreed to amend the existing credit agreement to provide covenant relief.
• The company will add three new independent directors to its board.
• The incremental term loan has a SOFR-based interest rate plus 7.50% with a 1.00% SOFR floor and matures on January 10, 2026.
• The company has the option to prepay the incremental term loan, subject to a prepayment fee.
• The proceeds of the incremental term loan are required to be deposited in a collateral account.
• The existing credit agreement was amended to include a SOFR-based interest rate plus 4.25% with a 1.00% SOFR floor for revolving loans.
• The default rate was amended to apply to all obligations upon an event of default.
• The term loan maturity date was amended to spring to July 2, 2029 if the second lien notes remain outstanding as of such date.
• Enhanced reporting requirements were added, and certain baskets were eliminated or reduced.
• Financial covenant relief was provided in the form of a covenant holiday and resetting of certain ratios.
• A minimum liquidity covenant of $25 million was established, tested weekly through April 11, 2025, monthly through June 30, 2025, and quarterly thereafter.
• A cash variance compliance test was added with respect to aggregate disbursements and receipts.
• The company will exchange $251 million in Senior Notes for Second Lien Notes, subject to certain conditions.
• Coliseum Capital Management has committed to purchase $30 million in Second Lien Notes and exchange $20 million in Senior Notes for Second Lien Notes, subject to stockholder approval.
• The company has withdrawn its previously stated revenue and adjusted EBITDA guidance for fiscal year 2024 and adjusted EBITDA growth for fiscal year 2025.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The new financing and leadership changes are positive, but the withdrawal of guidance and increased interest rates are negative. The overall sentiment is cautiously optimistic with significant risks.

Positives

• The new financing provides ModivCare with additional resources to focus on long-term strategic priorities.
• The appointment of a Chief Transformation Officer is intended to enhance operational performance.
• The strategic review of assets may lead to increased shareholder value.
• The covenant relief provides the company with more flexibility in the near term.

Negatives

• The company has withdrawn its previously stated revenue and adjusted EBITDA guidance for fiscal year 2024 and adjusted EBITDA growth for fiscal year 2025.
• The incremental term loan has a high interest rate of SOFR plus 7.50% with a 1.00% SOFR floor.
• The company is subject to a cash variance compliance test with respect to aggregate disbursements and receipts.
• The term loan maturity date was amended to spring to July 2, 2029 if the second lien notes remain outstanding as of such date.

Risks

• The company may not be successful in implementing its business plan.
• The company may not be able to generate sufficient cash to service all of its indebtedness.
• The company has experienced significant turnover in its senior management team and across its organization.
• Negotiations regarding new capital investment in the company may consume a substantial portion of the time and attention of management.
• The company may not be able to obtain stockholder approval for the Coliseum transaction.

Future Outlook

The company has withdrawn its previously stated revenue and adjusted EBITDA guidance for fiscal year 2024 and adjusted EBITDA growth for fiscal year 2025.

Management Comments

• This financing highlights broad-based support from stakeholders across the capital structure and provides the Company with additional resources to focus on long-term strategic priorities, said Heath Sampson, Chief Executive Officer and President of Modivcare.
• As we turn to the future, we are also excited to welcome Chad Shandler as Chief Transformation Officer. He brings a wealth of experience supporting large-scale transformations across the healthcare industry. Im looking forward to working with him, the Board and our financial partners to advance Modivcares strategic goals.
• The steps Modivcare is taking now to transform its business will ensure the Company is well positioned to connect people with the care they need, now and in the future, said Leslie Norwalk, Interim Chair of the Board.
• We and the leadership team have worked diligently to strengthen the Companys financial foundation and remain focused on improving the Companys operational performance with a view toward long-term growth.
• We are pleased to be able to provide this incremental financing to Modivcare, which will bolster its balance sheet and position the Company to achieve its long-term strategic priorities and deliver value to its stakeholders, said a representative of the supporting lenders.
• Modivcare plays a critical role in the countrys healthcare network with an important mission to connect people to care, wherever they are. As we continue to work with Modivcares leadership team and the Board, our goals are aligned in ensuring the Company is well positioned to continue to support its members nationwide.

Industry Context

The announcement reflects a trend of healthcare companies seeking financial stability and operational improvements through strategic transactions and leadership changes.

Comparison to Industry Standards

• The interest rate on the incremental term loan is higher than typical market rates, reflecting the company's financial challenges.
• The covenant relief provided is a common strategy for companies facing financial difficulties.
• The strategic review of assets is a typical response for companies seeking to maximize shareholder value.
• The appointment of a Chief Transformation Officer is a common step for companies undergoing significant operational changes.
• The withdrawal of guidance is a common occurrence for companies facing financial uncertainty.

Management Changes

Corporate Governance

Related Party Transactions

• Coliseum Capital Management has committed to purchase $30 million in Second Lien Notes and exchange $20 million in Senior Notes for Second Lien Notes, subject to stockholder approval.

Stakeholder Impact

• Shareholders face uncertainty due to the withdrawal of guidance and potential for further dilution.
• Lenders have increased their returns but also face increased risk.
• Employees may experience further changes due to the ongoing transformation.
• Customers may experience changes in service as the company implements its business plan.

Next Steps

• The company will seek stockholder approval for the Coliseum transaction.
• The company will continue to implement its business plan.
• The company will conduct a strategic review of its assets.
• The company will appoint three new independent directors to its board.

Key Dates

Keywords

financing, incremental term loan, second lien notes, covenant relief, strategic review, chief transformation officer, board of directors, liquidity, financial covenants, asset sales